A randomised controlled trial to compare the efficacy of preinduction with mifepristone 12 hours versus 24 hours prior for second trimister pregnancy termination
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20173498Keywords:
Mifepristone, Misoprostol, Second trimester, Termination of pregnancyAbstract
Background: Since the second trimester termination of pregnancy is on rise due to the detection of anomalies, this study aims to provide a safe regimen with respect to efficacy, side effects and acceptability for second trimester pregnancy termination.
Methods: It is a randomized controlled trial, conducted on 48 cases at BLDE Medical college, Vijayapur, Karnataka. They were divided into two groups; all patients were given mifepristone 200mg orally followed by misoprostol 400mcg vaginally after 12 hours in group I and 24 hours in group II respectively. Subsequent doses were decided depending on the Bishops score. Results were analyzed in terms of induction-abortion interval and dosage of misoprostol.
Results: The mean induction abortion interval was 563.9 minutes (9.3hrs) in group I and 714.6 minutes (11.9hrs) in group II; but was statistically not significant (p value 0.611) The total dose of misoprostol used was 783.3mcg in group I compared to 550mcg in group II, but was statistically not significant. The success rate was 100% in both the groups as none of them had incomplete abortion. There were no cases of uterine rupture, infection, need for check curettage and laparotomy.
Conclusions: Our study proves that the interval between mifepristone and misoprostol can be safely reduced to 12 hours without affecting the efficacy. But in gestational age <16 weeks and primigravida 24 hours interval may be of benefit. Both the regimens were 100% successful.
References
Paul M, Iyengar K, Iyengar S, Gemzell-danielsson K, Essén B, Klingberg-allvin M. Simplified follow-up after medical abortion using a low-sensitivity urinary pregnancy test and a pictorial instruction sheet in Rajasthan, India – study protocol and intervention adaptation of a randomised control trial. 2014;1-11.
Tripti N, Namrata S. Misoprostol vs mifepristone and misoprostol in second trimester termination of pregnancy. J Obstet Gynecol India. 2011;61(6):659-62.
Safe Abortion. Safe Abort Tech Policy Guid Heal Syst [Internet]. 2012; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23700650
Mathur M, Ashok P. An overview of medical abortion using low-dose mifepristone and misoprostol. Expert Rev Obstet Gynecol. 2007;2(3):371-8.
Misoprostol for second trimester abortion (query bank)August 2016 https://www.rcog.org.uk/en/guidelines-research-services/guidelines/misoprostol-for-second-trimester-abortion-query-bank/
Meena SR. Comparative study of mifepristone with vaginal misoprostol for first trimester termination of pregnancy at different gestatational ages. J Obstet Gynecol India. 2016;66(6):426-30.
Mentula M, Suhonen S, Heikinheimo O. One-and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancya randomized trial. Hum Reprod. 2011;26(10):2690-7.
Elami-Suzin M, Freeman MD, Porat N, Rojansky N, Laufer N, Ben-Meir A. Mifepristone Followed by Misoprostol or Oxytocin for Second-Trimester Abortion. Obstet Gynecol. 2013;122(4):815-20.
Kulkarni KK. Pre-induction with mifepristone for second trimester termination of pregnancy. J Obstet Gynecol India. 2014;64(2):102-4.
Sajjan GR, Patil N, Kaur M, Shirgur S, Nandi S, Ashwini V. Complete cervical avulsion with intravaginal misoprostol for second trimester pregnancy termination. Case Rep Obstet Gynecol. 2012;2012:1-3.
Constant D, Harries J, Malaba T, Myer L, Patel M, Petro G et al. Clinical outcomes and women’s experiences before and after the introduction of mifepristone into second-trimester medical abortion services in South Africa. PLoS One. 2016;11(9):1-14.
Gole S. FOGSI FOCUS Medical Abortion September 2011. Available fromhttps://issuu.com/fogsi/docs/medical_abortion_2011.
